1. Home
  2. ARBE vs CING Comparison

ARBE vs CING Comparison

Compare ARBE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

N/A

Current Price

$0.55

Market Cap

79.1M

Sector

Technology

ML Signal

N/A

CING

Cingulate Inc.

N/A

Current Price

$4.90

Market Cap

70.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARBE
CING
Founded
2015
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.1M
70.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
ARBE
CING
Price
$0.55
$4.90
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$2.75
★ $21.20
AVG Volume (30 Days)
★ 1.2M
88.0K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$301.71
N/A
Revenue Next Year
$427.31
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$3.16
52 Week High
$2.73
$11.89

Technical Indicators

Market Signals
Indicator
ARBE
CING
Relative Strength Index (RSI) 31.83 46.70
Support Level N/A $4.73
Resistance Level $0.91 $5.20
Average True Range (ATR) 0.04 0.25
MACD -0.01 -0.00
Stochastic Oscillator 16.93 42.75

Price Performance

Historical Comparison
ARBE
CING

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: